Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Statistical Communications in Infectious Diseases
|
February 25, 2026
Likelihood-based inferences for active-arm trial with counterfactual incidence based on recency assay
Yongwu Shao, Fei Gao
Statistics in Medicine
|
March 1, 2026
Likelihood Confidence Intervals for Misspecified Cox Models
Yongwu Shao, Xu Guo
Statistics in Medicine
|
August 7, 2024
Exact test and exact confidence interval for the Cox model
Yongwu Shao, Zhishen Ye, Zhiwei Zhang
Journal of the National Cancer Institute
|
January 14, 2011
Projections of the cost of cancer care in the United States: 2010-2020
Angela B Mariotto, K Robin Yabroff, Yongwu Shao, et al.
Gastroenterology
|
August 31, 2010
In the absence of HCV infection, interferon stimulated gene expression in liver is not associated with IL28B genotype
Fatma M Shebl, Dennis Maeder, Yongwu Shao, et al.
Clinical Pharmacology in Drug Development
|
April 30, 2016
Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus
Julia Zack, Jolene Berg, Axel Juan, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
September 20, 2025
Detection of HIV-1 drug resistance in RNA and proviral DNA genotyping is variable both longitudinally and during repeat testing
Michelle L D'Antoni, Kristen Andreatta, Silvia Chang, et al.
The Lancet. Child & Adolescent Health
|
September 1, 2018
Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial
Eva Natukunda, Aditya H Gaur, Pope Kosalaraksa, et al.
The Lancet. HIV
|
October 4, 2019
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
Franco Maggiolo, Giuliano Rizzardini, François Raffi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 14, 2020
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
Ignacio Perez-Valero, Josep M Llibre, Antonella Castagna, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Statistical Communications in Infectious Diseases
|
February 25, 2026
Likelihood-based inferences for active-arm trial with counterfactual incidence based on recency assay
Yongwu Shao, Fei Gao
Statistics in Medicine
|
March 1, 2026
Likelihood Confidence Intervals for Misspecified Cox Models
Yongwu Shao, Xu Guo
Statistics in Medicine
|
August 7, 2024
Exact test and exact confidence interval for the Cox model
Yongwu Shao, Zhishen Ye, Zhiwei Zhang
Journal of the National Cancer Institute
|
January 14, 2011
Projections of the cost of cancer care in the United States: 2010-2020
Angela B Mariotto, K Robin Yabroff, Yongwu Shao, et al.
Gastroenterology
|
August 31, 2010
In the absence of HCV infection, interferon stimulated gene expression in liver is not associated with IL28B genotype
Fatma M Shebl, Dennis Maeder, Yongwu Shao, et al.
Clinical Pharmacology in Drug Development
|
April 30, 2016
Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus
Julia Zack, Jolene Berg, Axel Juan, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
September 20, 2025
Detection of HIV-1 drug resistance in RNA and proviral DNA genotyping is variable both longitudinally and during repeat testing
Michelle L D'Antoni, Kristen Andreatta, Silvia Chang, et al.
The Lancet. Child & Adolescent Health
|
September 1, 2018
Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial
Eva Natukunda, Aditya H Gaur, Pope Kosalaraksa, et al.
The Lancet. HIV
|
October 4, 2019
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
Franco Maggiolo, Giuliano Rizzardini, François Raffi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 14, 2020
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
Ignacio Perez-Valero, Josep M Llibre, Antonella Castagna, et al.
Page
of 2